Sutro Biopharma Inc
STRO9.980USD
+1.050+11.76%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
84.93MMarket Cap
LossP/E TTM
More Details of Sutro Biopharma Inc Company
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Sutro Biopharma Inc Info
Ticker SymbolSTRO
Company nameSutro Biopharma Inc
IPO dateSep 27, 2018
CEOChung (Jane)
Number of employees310
Security typeOrdinary Share
Fiscal year-endSep 27
Address111 Oyster Point Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16503928412
Websitehttps://www.sutrobio.com/
Ticker SymbolSTRO
IPO dateSep 27, 2018
CEOChung (Jane)
Company Executives of Sutro Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
16.62K
+43.01%
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
12.29K
+11.33%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
5.37K
+3.09%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
2.25K
--
Dr. Barbara Leyman, Ph.D.
Dr. Barbara Leyman, Ph.D.
Chief Business Development Officer
Chief Business Development Officer
1.61K
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Mr. Joseph M. Lobacki
Mr. Joseph M. Lobacki
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Panek
Mr. James P. (Jim) Panek
Independent Director
Independent Director
--
--
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
16.62K
+43.01%
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
12.29K
+11.33%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
5.37K
+3.09%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
2.25K
--
Dr. Barbara Leyman, Ph.D.
Dr. Barbara Leyman, Ph.D.
Chief Business Development Officer
Chief Business Development Officer
1.61K
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Affinity Asset Advisors LLC
7.73%
Suvretta Capital Management, LLC
7.62%
Kynam Capital Management LP
5.97%
Millennium Management LLC
5.31%
The Vanguard Group, Inc.
4.32%
Other
69.05%
Shareholders
Shareholders
Proportion
Affinity Asset Advisors LLC
7.73%
Suvretta Capital Management, LLC
7.62%
Kynam Capital Management LP
5.97%
Millennium Management LLC
5.31%
The Vanguard Group, Inc.
4.32%
Other
69.05%
Shareholder Types
Shareholders
Proportion
Hedge Fund
38.90%
Investment Advisor/Hedge Fund
14.70%
Investment Advisor
9.87%
Corporation
3.20%
Venture Capital
2.81%
Individual Investor
1.50%
Research Firm
0.69%
Pension Fund
0.11%
Family Office
0.07%
Other
28.15%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
285
52.62M
61.82%
-30.92M
2025Q2
293
65.52M
77.57%
-18.74M
2025Q1
295
63.49M
75.19%
-18.52M
2024Q4
299
65.68M
79.84%
-13.78M
2024Q3
295
64.44M
78.61%
-17.80M
2024Q2
286
64.98M
79.66%
-15.82M
2024Q1
291
55.64M
88.75%
-15.66M
2023Q4
302
58.38M
95.62%
-12.57M
2023Q3
306
61.36M
101.61%
-9.98M
2023Q2
312
60.26M
100.55%
-11.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Affinity Asset Advisors LLC
752.72K
0.89%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
6.49M
7.65%
-974.17K
-13.05%
Jun 30, 2025
Kynam Capital Management LP
5.09M
6%
-353.35K
-6.49%
Jun 30, 2025
Millennium Management LLC
4.73M
5.58%
+4.03M
+573.00%
Jun 30, 2025
The Vanguard Group, Inc.
4.12M
4.85%
-279.99K
-6.37%
Jun 30, 2025
Acadian Asset Management LLC
3.04M
3.59%
-92.35K
-2.95%
Jun 30, 2025
Velan Capital Investment Management LP
3.06M
3.61%
+2.03M
+197.09%
Jun 30, 2025
Tang Capital Management, LLC
2.56M
3.02%
+2.36M
+1180.79%
Jun 30, 2025
Merck & Co Inc
2.72M
3.21%
--
--
Jun 30, 2025
Vestal Point Capital, LP
2.60M
3.07%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares US Small-Cap Equity Factor ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Avantis US Small Cap Equity ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares US Small-Cap Equity Factor ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Sutro Biopharma Inc?
The top five shareholders of Sutro Biopharma Inc are:
Affinity Asset Advisors LLC holds 752.72K shares, accounting for 0.89% of the total shares.
Suvretta Capital Management, LLC holds 6.49M shares, accounting for 7.65% of the total shares.
Kynam Capital Management LP holds 5.09M shares, accounting for 6.00% of the total shares.
Millennium Management LLC holds 4.73M shares, accounting for 5.58% of the total shares.
The Vanguard Group, Inc. holds 4.12M shares, accounting for 4.85% of the total shares.
Affinity Asset Advisors LLC holds 752.72K shares, accounting for 0.89% of the total shares.
Suvretta Capital Management, LLC holds 6.49M shares, accounting for 7.65% of the total shares.
Kynam Capital Management LP holds 5.09M shares, accounting for 6.00% of the total shares.
Millennium Management LLC holds 4.73M shares, accounting for 5.58% of the total shares.
The Vanguard Group, Inc. holds 4.12M shares, accounting for 4.85% of the total shares.
What are the top three shareholder types of Sutro Biopharma Inc?
The top three shareholder types of Sutro Biopharma Inc are:
Affinity Asset Advisors LLC
Suvretta Capital Management, LLC
Kynam Capital Management LP
Affinity Asset Advisors LLC
Suvretta Capital Management, LLC
Kynam Capital Management LP
How many institutions hold shares of Sutro Biopharma Inc (STRO)?
As of 2025Q3, 285 institutions hold shares of Sutro Biopharma Inc, with a combined market value of approximately 52.62M, accounting for 61.82% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -15.75%.
What is the biggest source of revenue for Sutro Biopharma Inc?
In --, the -- business generated the highest revenue for Sutro Biopharma Inc, amounting to -- and accounting for --% of total revenue.
